{"id":70648,"date":"2026-05-12T08:47:35","date_gmt":"2026-05-12T08:47:35","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70648"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"semaglutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/semaglutide\/","title":{"rendered":"Semaglutide"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Semaglutide?<\/h3>\n

Semaglutide<\/strong> is a 31-amino-acid GLP-1 receptor agonist peptide and the active research molecule behind Ozempic, Wegovy, and Rybelsus. It is the most extensively studied long-acting GLP-1 analog in published research, with a plasma half-life of approximately 165 hours (~7 days) enabling once-weekly dosing protocols. Supplied in 2\u00a0mg to 50\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

What you get with MedsBase:<\/strong> Research-grade lyophilized peptides \u00b7 HPLC \u226599% purity (COA on request) \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide peptide courier \u00b7 1,400+ verified customer reviews<\/a><\/div>\n

\ud83d\udce6 Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specification<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS Number<\/strong><\/td>\n910463-68-2<\/td>\n<\/tr>\n
Molecular Formula<\/strong><\/td>\nC187<\/sub>H291<\/sub>N45<\/sub>O59<\/sub><\/td>\n<\/tr>\n
Molecular Weight<\/strong><\/td>\n4113.58 Da<\/td>\n<\/tr>\n
Sequence<\/strong><\/td>\nH-Aib-EGTFTSDVSSYLEGQAAK(N\u03b5-(N-(17-carboxy-1-oxoheptadecyl)-L-\u03b3-glutamyl)-[2-(2-aminoethoxy)ethoxy]acetyl-[2-(2-aminoethoxy)ethoxy]acetyl)EFIAWLVRGRG-OH (31 aa, GLP-1[7-37] backbone with Aib8<\/sup>, Arg34<\/sup>, and Lys26<\/sup>-fatty acid acylation)<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyophilized powder (white to off-white)<\/td>\n<\/tr>\n
Purity<\/strong><\/td>\n\u226599% (HPLC verified, COA on request)<\/td>\n<\/tr>\n
Storage<\/strong><\/td>\nLyophilized: 2\u20138\u00a0\u00b0C (refrigerator) for working stock; \u221220\u00a0\u00b0C for long-term storage of unopened vials. Reconstituted: 2\u20138\u00a0\u00b0C, use within ~30 days. Protect from light. Do not freeze\u2013thaw the reconstituted solution.<\/td>\n<\/tr>\n
Solubility<\/strong><\/td>\nBacteriostatic water (recommended) or sterile water for shorter use windows<\/td>\n<\/tr>\n
Research Use<\/strong><\/td>\nFor laboratory research use only. Not for human or veterinary diagnostic or therapeutic use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Semaglutide?<\/h2>\n

Semaglutide<\/strong> is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed as a structural analog of the endogenous incretin hormone GLP-1. It is a 31-amino-acid peptide built on the GLP-1(7-37) backbone with three engineered modifications that distinguish it from earlier short-acting analogs: an \u03b1-aminoisobutyric acid (Aib) substitution at position 8 that resists DPP-4 cleavage, an arginine substitution at position 34 to prevent off-target acylation, and a C18 fatty diacid attached at lysine 26 via a \u03b3-glutamic acid and two 2-(2-aminoethoxy)ethoxyacetic acid (AEEA) spacers. The fatty-acid tether drives strong reversible binding to circulating albumin, extending the plasma half-life to approximately 165 hours and making semaglutide the longest-acting GLP-1 agonist developed to date for once-weekly subcutaneous dosing in published research.<\/p>\n

Semaglutide’s peptide sequence and molecular structure are well-characterised: empirical formula C187<\/sub>H291<\/sub>N45<\/sub>O59<\/sub>, average molecular weight 4113.58 Da. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Pharmaceutical semaglutide is approved by the FDA, EMA, and MHRA under the brand names Ozempic (subcutaneous, type 2 diabetes), Wegovy (subcutaneous, chronic weight management), and Rybelsus (oral, type 2 diabetes). The research-grade semaglutide sold here is for laboratory research use only<\/strong> and is not FDA-approved for human or veterinary administration. For a deep dive on mechanism, pharmacokinetics, and head-to-head trial data, see our full Retatrutide vs Tirzepatide guide<\/a> and the broader research peptides catalog<\/a>.<\/p>\n

Mechanism of Action \u2014 GLP-1 Receptor Signaling Across Three Tissue Compartments<\/h2>\n

What makes semaglutide more pharmacologically interesting than earlier GLP-1 analogs (liraglutide, exenatide) is the combination of high receptor selectivity with a half-life long enough to maintain near-continuous receptor occupancy. Published research has mapped its activity across three distinct tissue compartments<\/strong>, each contributing to the observed metabolic phenotype:<\/p>\n